Maladie de Behçet en gynécologie-obstétrique

Thubert, Thibault; Donnadieu, A; C, Dupont-Bernabé; Even, Marc; Fior, R; Pasquali, J L; Frydman, René; Benachi, Alexandra; Picone, Olivier

doi:10.1016/j.jgyn.2010.06.012

Cited by 2 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small number of case reports describe transient neonatal BD mostly consisting of oral or genital ulcerations and skin findings that resolve up to 8 weeks after birth [ 83 , 88 , 89 ]. One neonatal death occurred from respiratory distress and neurological involvement following delivery at 34 weeks of gestation and another neonate, born at 38 weeks, suffered life-threatening complications a few days postpartum treated with glucocorticoids [ 90 , 91 ].…”

Section: Behçet’s Diseasementioning

confidence: 99%

Pregnancy Outcomes in Systemic Vasculitides

2020

View full text Add to dashboard Cite

Purpose of Review In recent years, improvements in the recognition of primary vasculitides and increased treatment options have led to greater survival rates and a better quality of life for patients. Therefore, pregnancy in women with vasculitis has become a more frequent consideration or event. Literature on pregnancy outcomes in this population has grown and allowed us, in this article, to review the effects of pregnancy on disease activity, as well as maternal and fetal outcomes for each type of vasculitides. Recent Findings Successful pregnancies in patients with vasculitides are possible, especially when conception is planned, and the disease is in remission. The risk of vasculitis flare is highly dependent on the type of vasculitis, but overall limited. The most frequent complication associated with large-vessel vasculitis (mainly Takayasu arteritis) is hypertension and preeclampsia. Preterm deliveries and intrauterine growth restriction occur more frequently with small-and medium-vessel vasculitis. Summary Pregnancies in patients with vasculitis should be considered high risk and followed by a multidisciplinary team with expertise in the field. Flares should be managed as in the non-pregnant population, while avoiding medications with unknown safety in pregnancy or known teratogens. Although commonly prescribed for the prevention of preeclampsia, there is limited evidence supporting the use of low-dose aspirin for pregnant women with vasculitis. Prospective registries or studies are needed, to better assess the value of aspirin, the place and long-term impact of new biologics and, to identify predictors of pregnancy outcomes other than disease status at conception.

show abstract